Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01042366 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | Phase 2 | terminated | Jan 5, 2010 | John Kirkwood | Closed to accrual in March 2009 for slow accrual. | Enrollment / accrual |
| NCT00871533 | Pilot Study of IFN α2b for Melanoma Patients | Early Phase 1 | terminated | Mar 30, 2009 | University of Pittsburgh | not stated | Not stated |
| NCT01271907 | Drosophila-generated CTL | Phase 2 | terminated | Jan 7, 2011 | National Cancer Institute (NCI) | Study was terminated due to withdrawal of CRADA partner. | Other (stated, no rule matched) |
| NCT02663258 | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)(ADAPTeM) | Phase 2 | withdrawn | Jan 26, 2016 | Royal Marsden NHS Foundation Trust | not stated | Not stated |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With… | Phase 1 | withdrawn | Jul 3, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01067066 | A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | Phase 1 | terminated | Feb 11, 2010 | M.D. Anderson Cancer Center | Phase I/II study halted as Phase I, Low Response Rate | Other (stated, no rule matched) |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Phase 1 | withdrawn | Aug 6, 2014 | M.D. Anderson Cancer Center | Issues with tetramer staining | Other (stated, no rule matched) |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic… | Phase 2 | terminated | Feb 24, 2009 | GlaxoSmithKline | Early end of trial notification after termination of long term follow up due to lack of scientific… | Other (stated, no rule matched) |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | Phase 1 / Phase 2 | terminated | Jun 19, 2009 | University of Iowa | Change in the number of approved drugs for metastatic melanoma | Other (stated, no rule matched) |
| NCT01701037 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients… | Phase 2 | terminated | Oct 4, 2012 | Vanderbilt-Ingram Cancer Center | PI leaving VICC, low future accrual predicted, continued funding improbable, | Enrollment / accrual |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | Phase 1 | terminated | Aug 4, 2011 | M.D. Anderson Cancer Center | Slow accrual, closed in Phase I. | Enrollment / accrual |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage… | Phase 2 | terminated | Apr 26, 2012 | Genentech, Inc. | Recruitment challenges | Enrollment / accrual |
| NCT01843738 | Radiation Use During Vemurafenib Treatment | Phase 1 | withdrawn | May 1, 2013 | University of Utah | Competing Trials | Other (stated, no rule matched) |
| NCT02236546 | FDG-PET in Advanced Melanoma | N/A | terminated | Sep 10, 2014 | Vanderbilt-Ingram Cancer Center | loss of funding | Funding |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | Phase 2 | terminated | Mar 13, 2012 | Dana-Farber Cancer Institute | due to weak accrual | Enrollment / accrual |
| NCT01754376 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | Phase 2 | terminated | Dec 21, 2012 | Massachusetts General Hospital | changes in available treatments for melanoma | Other (stated, no rule matched) |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With… | Phase 1 / Phase 2 | terminated | Apr 10, 2015 | Celldex Therapeutics | Feasibility concerns due to changes in standard of care | Other (stated, no rule matched) |
| NCT01611675 | Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | Phase 1 | terminated | Jun 5, 2012 | Massachusetts General Hospital | Adverse Events | Safety / toxicity |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | Phase 1 / Phase 2 | terminated | Dec 4, 2009 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00707161 | Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or… | Phase 2 | terminated | Jun 30, 2008 | University of Utah | discontinued due to low enrollment | Enrollment / accrual |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye… | Phase 2 | terminated | Jun 5, 2007 | National Institutes of Health Clinical Center (CC) | Investigator left the institute. | Investigator |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | Phase 2 | terminated | Jan 28, 2008 | Novo Nordisk A/S | See termination reason in detailed description | Other (stated, no rule matched) |
| NCT01705392 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | Phase 2 | terminated | Oct 12, 2012 | Haukeland University Hospital | Lack of financing of the study drug. Not sufficient financial support. | Funding |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | Phase 2 | withdrawn | Mar 27, 2015 | California Pacific Medical Center Research Institute | With recent advances in immunotherapy scientific question not significant | Other (stated, no rule matched) |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | Phase 2 | terminated | Oct 30, 2007 | National Institutes of Health Clinical Center (CC) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced…(LOGIC) | Phase 2 | terminated | Mar 28, 2013 | Array BioPharma | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT01984255 | A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced… | Phase 1 | terminated | Nov 14, 2013 | University of Texas Southwestern Medical Center | standard of care improved combination treatment of ipilimumab plus nivolumab. | Other (stated, no rule matched) |
| NCT00977145 | Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a…(Mel 51) | Phase 1 | terminated | Sep 15, 2009 | Craig L Slingluff, Jr | Closed short of the enrollment goal, due to slow enrollment and adequate data to address endpoints | Enrollment / accrual |
| NCT00068666 | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma… | Phase 2 | terminated | Sep 11, 2003 | Alliance for Clinical Trials in Oncology | not stated | Not stated |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for… | Phase 1 / Phase 2 | terminated | Jun 27, 2013 | Virogen Biotechnology Inc. | Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab) | Other (stated, no rule matched) |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | Phase 1 | terminated | Sep 25, 2013 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Local IRB required us to submit amendment as a separate study. | Other (stated, no rule matched) |
| NCT02427893 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | Phase 3 | withdrawn | Apr 28, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | no patients were enrolled | Enrollment / accrual |
| NCT01765556 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in… | Phase 1 | withdrawn | Jan 10, 2013 | Hoffmann-La Roche | not stated | Not stated |
| NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | Phase 2 | terminated | Oct 31, 2013 | EMD Serono | The study is terminated prematurely as the sponsor decided to discontinue program of NHS-IL2… | Sponsor / business decision |
| NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | Phase 1 | terminated | Dec 25, 2009 | M.D. Anderson Cancer Center | Poor Accrual | Enrollment / accrual |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in… | Phase 2 | terminated | Mar 3, 2011 | National Cancer Institute (NCI) | Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative… | Efficacy / futility |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma… | Phase 1 | terminated | Jan 26, 2012 | Hoffmann-La Roche | Study was terminated due to low enrollment. | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With…(MRX34-102) | Phase 1 / Phase 2 | withdrawn | Aug 10, 2016 | Mirna Therapeutics, Inc. | 5 immune related serious adverse events in Phase 1 study | Safety / toxicity |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | Phase 1 / Phase 2 | terminated | Jan 29, 2013 | Array BioPharma | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic… | Phase 2 | terminated | Mar 25, 2010 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With… | Phase 1 / Phase 2 | terminated | Mar 9, 2010 | Nantes University Hospital | not stated | Not stated |
| NCT01605162 | Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With… | Phase 2 | terminated | May 24, 2012 | Eisai Inc. | not stated | Not stated |
| NCT01312506 | Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma… | — | withdrawn | Mar 10, 2011 | University of Pittsburgh | Trial experienced funding issues, was never opened to accrual. | Enrollment / accrual |
| NCT00724841 | A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of… | Phase 1 / Phase 2 | terminated | Jul 30, 2008 | Gemin X | Study terminated prematurely due to financial contraints. | Funding |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | Phase 2 | terminated | Nov 10, 2011 | National Cancer Institute (NCI) | Study was closed prematurely due to slow and insufficient accrual. | Enrollment / accrual |
| NCT02062359 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing… | Phase 2 | terminated | Feb 13, 2014 | National Cancer Institute (NCI) | Study was closed due to poor accrual. | Enrollment / accrual |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | May 10, 2010 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01557114 | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With…(Mel-Ipi-Rx) | Phase 1 | terminated | Mar 19, 2012 | Gustave Roussy, Cancer Campus, Grand Paris | New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 16, 2017source: clinicaltrials